Annexon reports inducement grant to new employee under nasdaq listing rule 5635(c)(4)

Brisbane, calif., april 16, 2025 (globe newswire) -- annexon, inc. (nasdaq: annx), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 employment inducement award plan. the equity award was approved on april 11, 2025, in accordance with nasdaq listing rule 5635(c)(4).
ANNX Ratings Summary
ANNX Quant Ranking